Literature DB >> 10519407

Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.

C O Rodriguez1, V Gandhi.   

Abstract

9-Beta-D-Arabinosylguanine (ara-G) is a recently introduced and effective treatment for T-cell acute lymphoblastic leukemia, but how ara-G and ara-G triphosphate (ara-GTP) kill cells is not known. We hypothesized that, in cycling T-lymphoblastoid cells, ara-G may act directly by incorporation into DNA, which may lead to apoptosis. Hence, blocking the incorporation of ara-G monophosphate (ara-GMP) into DNA may prevent apoptosis. To test this hypothesis, we performed experiments in a T-lymphoblastic leukemia cell line (CCRF-CEM) after synchronization with a double aphidicolin block. Intracellular accumulation of ara-GTP was neither cell cycle dependent nor affected by aphidicolin (53 +/- 5 microM/h without aphidicolin, 50 +/- 5 microM/h with aphidicolin). Cells at the G1-S boundary accumulated 75 +/- 7 microM ara-GTP with minimal incorporation into DNA (5 +/- 2 pmol ara-GMP/mg DNA) and had little biochemical or morphological evidence of apoptosis. In marked contrast, cells in S phase had significantly more ara-G incorporated into DNA (24 +/- 4 pmol ara-GMP/mg DNA), although the cytosolic concentration of ara-GTP (85 +/- 7 microM) was similar to that in the G1-enriched population. In the S-phase cells, there was a corresponding increase in apoptosis (measured as high molecular weight DNA fragmentation and morphological changes), and the incorporation of ara-GTP into DNA resulted in a >95% inhibition of DNA synthesis. There was a direct linear relationship between the number of cells in S phase and both the total number of ara-GMP molecules in DNA and the inhibition of DNA synthesis. Blocking of ara-GTP incorporation into S-phase DNA abolished biochemical and morphological features of apoptosis, even in the presence of cytotoxic level of intracellular ara-GTP. Taken together, these data demonstrate that the incorporation of ara-GTP into DNA is the critical event that mediates the induction of apoptosis in CCRF-CEM cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519407

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma.

Authors:  Adele K Fielding; Lalita Banerjee; David I Marks
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 2.  Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Tapan M Kadia; Varsha Gandhi
Journal:  Expert Rev Hematol       Date:  2016-12-08       Impact factor: 2.929

3.  Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade.

Authors:  Hanying Wang; Xin He; Lei Zhang; Haojie Dong; Feiteng Huang; Jie Xian; Min Li; Wei Chen; Xiyuan Lu; Khyatiben V Pathak; Wenfeng Huang; Zheng Li; Lianjun Zhang; Le Xuan Truong Nguyen; Lu Yang; Lifeng Feng; David J Gordon; Jing Zhang; Patrick Pirrotte; Chun-Wei Chen; Amandeep Salhotra; Ya-Huei Kuo; David Horne; Guido Marcucci; David B Sykes; Stefano Tiziani; Hongchuan Jin; Xian Wang; Ling Li
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

4.  Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Kelly M Reilly; David F Kisor
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

5.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01

Review 6.  Treatment of acute lymphoblastic leukaemia : a new era.

Authors:  Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis J Giles
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.

Authors:  Tadashi Kumamoto; Hiroaki Goto; Chitose Ogawa; Toshinori Hori; Takao Deguchi; Takuya Araki; Akiko M Saito; Atsushi Manabe; Keizo Horibe; Hidemi Toyoda
Journal:  Int J Hematol       Date:  2020-08-06       Impact factor: 2.490

8.  Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.

Authors:  Lydia Lee; Adele K Fielding
Journal:  Clin Med Insights Oncol       Date:  2012-01-22

9.  NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir.

Authors:  Rina Nishii; Takanori Mizuno; Daniel Rehling; Colton Smith; Brandi L Clark; Xujie Zhao; Scott A Brown; Brandon Smart; Takaya Moriyama; Yuji Yamada; Tatsuo Ichinohe; Makoto Onizuka; Yoshiko Atsuta; Lei Yang; Wenjian Yang; Paul G Thomas; Pål Stenmark; Motohiro Kato; Jun J Yang
Journal:  Nat Commun       Date:  2021-07-07       Impact factor: 14.919

10.  Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Authors:  Todd M Cooper
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.